Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Dosage Comparison: BPC-157 vs TB-500

The dosing philosophy differs fundamentally between these two peptides. BPC-157 has a short half-life and requires daily administration. TB-500 has a long half-life and uses a loading/maintenance approach. The table below provides a side-by-side comparison. Lo

This comparison does not assign a generated winner or score.

  • The dosing philosophy differs fundamentally between these two peptides. BPC-157 has a short half-life and requires daily administration. TB-500 has a long half-life and uses a loading/maintenance approach. The table below provides a side-by-side comparison.
  • Loading dose
  • Not required
  • 5-10 mg/week for 4-6 weeks
  • 2.5-5 mg/week (maintenance)
  • Severe injury dose
  • 500 mcg/day
  • 10 mg/week (loading)
  • Mild injury dose
  • 250 mcg/day
  • 5 mg/week (loading)
  • Frequency
  • 1-2x daily
  • 2-3x weekly (loading), 1-2x weekly (maintenance)
  • Cycle length
  • 4-8 weeks
  • 8-12 weeks total
  • Reconstitution
  • 5 mg vial + 2.5 mL bac water = 2 mg/mL
  • 5 mg vial + 2 mL bac water = 2.5 mg/mL
  • Injection route
  • Subcutaneous (near injury) or oral
  • Subcutaneous (abdomen or thigh)
  • Units per dose
  • 12.5-25 units (at 2 mg/mL on insulin syringe)
  • 100 units / 1 mL (at 2.5 mg/mL for 2.5 mg)
  • Why BPC-157 needs daily dosing. Its half-life is roughly 4 hours. By the 8-hour mark, plasma levels have dropped to about 25% of peak. Daily injections maintain therapeutic concentrations at the injury site. Some users split the daily dose into two injections (morning and evening) for more stable levels.
  • Why TB-500 uses loading/maintenance. Its 7-10 day half-life allows tissue levels to accumulate over weeks. The loading phase saturates the body's repair machinery. Skipping the loading phase is the most common TB-500 dosing mistake. Users who start at maintenance doses (2.5 mg/week) often see no results for 6-8 weeks, then assume the peptide is ineffective.
  • Use the peptide dosage chart for cross-reference with other compounds, and the peptide reconstitution calculator for exact mixing volumes.
More references

Related material

Comparison

BPC-157 vs TB-500

BPC-157 vs TB-500 A 2026 UK research comparison of BPC-157 and TB-500 — two distinct peptides with overlapping preclinical evidence in tendon, ligament and muscle repair. Mechanis…

View details →
Comparison

BPC-157 vs TB-500

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

View details →
Comparison

3. Mechanism comparison

BPC-157 mechanism (primary axes): VEGFR2 activation → angiogenesis FAK-paxillin pathway → fibroblast migration Nitric oxide system modulation EGR1 pathway engagement Protection ag…

View details →